Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03490292 · ClinicalTrials.gov registry record · Phase 1

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

A Phase 1 study of GastroEsophageal Cancer and Resectable Esophageal Cancer, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT03490292 is a Phase 1 study of GastroEsophageal Cancer and Resectable Esophageal Cancer that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 22 participants, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03490292, a Phase 1 study of GastroEsophageal Cancer and Resectable Esophageal Cancer, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy of avelumab in combination with chemoradiation in patients with resectable esophageal and gastroesophageal cancer. Part 1: This is the run-in phase of the trial. This portion will determine the safety and tolerability of avelumab in combination with chemoradiotherapy in 6 patients. The proposed combination will be considered as safe if dose limiting toxicities are observed in at most 1 patient. Part 2: This is a Phase 2 portion of the trial, which will evaluate the efficacy of the proposed treatment regimen in patients with stage II/III resectable esophageal and gastroesophageal cancer

Conditions Studied

GastroEsophageal Cancer Resectable Esophageal Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • RADIATION Radiation
  • COMBINATION_PRODUCT Avelumab combined with Chemoradiation

Study Locations (1)

Wisconsin

  • University of Wisconsin Carbone Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-05-29
Est. Completion 2023-07-12
Phase Phase 1

Sponsor

University of Wisconsin, Madison

1,039 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03490292

The ClinicalTrials.gov registry entry for NCT03490292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT03490292 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03490292 about?

NCT03490292 is a clinical study titled "Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer". This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy of avelumab in combination with chemoradiation in patients with resectable esophageal and gastroesophageal cancer. Part 1: This is the run-in phase of the trial. This portion will determine the safety and to...

What is the current status of trial NCT03490292?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-05-29. Estimated completion is 2023-07-12.

What conditions does trial NCT03490292 study?

This clinical trial studies the following conditions: GastroEsophageal Cancer, Resectable Esophageal Cancer.

What interventions are being tested in trial NCT03490292?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiation (RADIATION), Avelumab combined with Chemoradiation (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03490292?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03490292 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for GastroEsophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

GastroEsophageal Cancer

All registered trials for this condition

Resectable Esophageal Cancer

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.